HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nonprofit Pharmaceutical Companies

756.444

+3.6790.49%

Number of Gainers:14

Number of Losers:19

Number of Flat:1

PE:- -

High:759.807

Open:752.766

Low:731.811

Close:752.766

Volume:245.95M

Turnover:5.87B

Market Cap:446.90B

Float Cap:412.47B

Loading ...

Alphamab Oncology's IND Application for Innovative Cancer Drug JSKN022 Accepted by China's CDE

BRIEF-Everest Medicines Expands Strategic Investment In I-Mab

Everest Medicines Expands Strategic Investment in I-Mab

THOMSON REUTERS

New Horizon Health's Liquidator Application to Be Heard Aug. 6

MT Newswires Live

Everest Medicines Ltd. Expands Stake with $30.9 Million Investment in U.S.-Based Biotech Firm I-Mab

Everest Medicines - Subscribes for 15.8 Mln Adss of I-Mab for $30.9 Mln

THOMSON REUTERS

Everest Medicines Ltd. Completes Private Placement and Top-Up Subscription of Shares Under General Mandate

Everest Medicines Ltd. Files Next Day Disclosure Return with HKEX Announcing Increase of 143,305 New Shares at HKD 19.64 Per Share

Ascentage Pharma to Participate in Evercore China Biotech Summit in Shanghai

NH HEALTH (06606): Joint Provisional Liquidators Application Filed, Trading Suspension Continues

New Horizon Health Ltd. Applies for Joint Provisional Liquidators to Protect Shareholder Interests Amid Trading Suspension

AH Statistics | August 1st

UBS Reiterates "Buy" Rating on AKESO (09926), Raises Target Price to HK$197.5

A-Share Market Review: Trading Volume Shrinks by Over 300 Billion Yuan, Three Major Indices Close Slightly Lower While Pharmaceutical Stocks Maintain Strength

112% Returns at Peak Before Sudden Departure? Yongying Fund's Chu Kefan Resignation Sparks Speculation as "Steady Innovation" Strategy Shows Success Only in Healthcare

CARsgen Therapeutics Holdings Ltd. Announces Upcoming Board Meeting to Review Interim Results

Kintor Pharmaceutical Ltd. Announces Top-Up Placing and New Share Subscription Under General Mandate

BRIEF-Kintor Pharmaceutical To Issue 20.7 MLN Shares For HK$2.08 Per Share

Kintor Pharmaceutical - to Issue 20.7 Mln Shares for HK$2.08 per Share

THOMSON REUTERS

Kintor Pharmaceutical Completes Patient Enrollment for Phase III Trial of KX-826 Tincture for Male AGA Treatment in China

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1574/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":756.4441,"timestamp":1754640483916,"preClose":752.76556,"halted":0,"volume":245946369,"delay":0,"changeRate":0.004887,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":3.678528,"latestTime":"08-08 16:00:00","open":752.76556,"high":759.8065,"low":731.8107,"amount":5871661389.5,"amplitude":0.037191,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1754875800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1754616600000,1754625600000],[1754629200000,1754640000000]],"pbRate":6.123728,"peRate":-38.625124,"turnoverRate":0.009192,"increases":14,"decrements":17,"flats":2,"marketCap":446904094912,"floatMarketCap":412466656768},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":759.8065,"amplitude":0.037191,"preClose":752.76556,"low":731.8107,"pbRate":"6.123728","latestPrice":756.4441,"volume":245946369,"delay":0,"open":752.76556,"prevYearClose":331.1933,"prevWeekClose":721.922,"prevMonthClose":735.033,"prevQuarterClose":555.617,"fiveDayClose":721.922,"twentyDayClose":607.346,"sixtyDayClose":449.278,"secType":"PLATE","market":"HK","turnoverRate":0.009192,"peRate":-38.625124,"marketCap":446904094912,"floatMarketCap":412466656768,"timestamp":1754640483916,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":14,"down":19,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2556827978","title":"Alphamab Oncology's IND Application for Innovative Cancer Drug JSKN022 Accepted by China's CDE","url":"https://stock-news.laohu8.com/highlight/detail?id=2556827978","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556827978?lang=en_us&edition=fundamental","pubTime":"2025-08-03 18:17","pubTimestamp":1754216239,"startTime":"0","endTime":"0","summary":"Alphamab Oncology has announced that their Investigational New Drug  application for JSKN022 has been officially accepted by the Center for Drug Evaluation  of the National Medical Products Administration of China. JSKN022 is an innovative bispecific antibody-drug conjugate targeting programmed death ligand 1  and integrin αvβ6, developed independently by Alphamab. This marks a significant step forward as there are currently no approved ADCs targeting integrin αvβ6 or PD-L1 globally. The company plans to commence a first-in-human clinical study for treating advanced malignant solid tumors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphamab Oncology published the original content used to generate this news brief on August 03, 2025,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250803:nNDL1TmR4T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1574","BK1161"],"gpt_icon":0},{"id":"2556681134","title":"BRIEF-Everest Medicines Expands Strategic Investment In I-Mab","url":"https://stock-news.laohu8.com/highlight/detail?id=2556681134","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556681134?lang=en_us&edition=fundamental","pubTime":"2025-08-01 21:49","pubTimestamp":1754056176,"startTime":"0","endTime":"0","summary":"BRIEF-Everest Medicines Expands Strategic Investment In I-MabEverest Medicines Ltd 1952.HK:EVEREST MEDICINES EXPANDS STRATEGIC INVESTMENT IN I-MABSource text: ID:nPn4r2s6QaFurther company coverage: 1952.HK","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250801:nTUA6JCYKQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952","BK1161","BK1583","BK1574"],"gpt_icon":0},{"id":"2556781662","title":"Everest Medicines Expands Strategic Investment in I-Mab","url":"https://stock-news.laohu8.com/highlight/detail?id=2556781662","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556781662?lang=en_us&edition=fundamental","pubTime":"2025-08-01 20:56","pubTimestamp":1754052987,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250801:nTUA6JCYKQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","01952","BK1583","BK1161"],"gpt_icon":0},{"id":"2556816669","title":"New Horizon Health's Liquidator Application to Be Heard Aug. 6","url":"https://stock-news.laohu8.com/highlight/detail?id=2556816669","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556816669?lang=en_us&edition=fundamental","pubTime":"2025-08-01 20:46","pubTimestamp":1754052412,"startTime":"0","endTime":"0","summary":"The hearing of New Horizon Health's  joint provisional liquidator application with the Grand Court of the Cayman Islands has been scheduled at 10 am on Aug. 6, a Friday Hong Kong bourse filing said.The cancer screening test developer had filed the application in early July.If appointed, the joint provisional liquidators will conduct investigations into the firm's affairs, in particular, certain concerns raised by the company's auditors in relation to its 2023 annual results.The auditor raised questions on the validity of certain sales transactions, as well as marketing and selling expenses among other things, according to a March 2024 disclosure.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06606","BK1219","BK1574"],"gpt_icon":0},{"id":"2556668815","title":"Everest Medicines Ltd. Expands Stake with $30.9 Million Investment in U.S.-Based Biotech Firm I-Mab","url":"https://stock-news.laohu8.com/highlight/detail?id=2556668815","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556668815?lang=en_us&edition=fundamental","pubTime":"2025-08-01 20:17","pubTimestamp":1754050665,"startTime":"0","endTime":"0","summary":"Everest Medicines Ltd., a biopharmaceutical company, has expanded its portfolio by subscribing to 15,846,154 American depositary shares of I-Mab, a U.S.-based biotech company specializing in precision immuno-oncology agents. The transaction, valued at approximately US$30.9 million, enhances Everest Medicines' stake in I-Mab to 16.1% of its total issued share capital. This strategic move aligns with Everest Medicines' commitment to advancing novel therapies addressing critical unmet medical needs. The company continues to build its portfolio of first-in-class or best-in-class products, further solidifying its presence in the global biotech industry.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everest Medicines Ltd. published the orig","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250801:nNDL9T24Wl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4505","BK4139","BK1583","01952","IMAB","BK1574","BK1161","BK4526"],"gpt_icon":0},{"id":"2556815564","title":"Everest Medicines - Subscribes for 15.8 Mln Adss of I-Mab for $30.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2556815564","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556815564?lang=en_us&edition=fundamental","pubTime":"2025-08-01 20:13","pubTimestamp":1754050383,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250801:nFWN3TT1IJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1574","BK1161","01952"],"gpt_icon":0},{"id":"2556290818","title":"Everest Medicines Ltd. Completes Private Placement and Top-Up Subscription of Shares Under General Mandate","url":"https://stock-news.laohu8.com/highlight/detail?id=2556290818","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556290818?lang=en_us&edition=fundamental","pubTime":"2025-08-01 19:39","pubTimestamp":1754048366,"startTime":"0","endTime":"0","summary":"Everest Medicines Limited, incorporated in the Cayman Islands and listed under Stock Code 1952, has announced the completion of a placing of existing shares and a top-up subscription of new shares under a general mandate. The company successfully placed an aggregate of 22,561,000 sale shares through placement agents, on a best effort basis, to not less than six placees, at a purchase price of HK$69.70 per sale share. This strategic move is part of the company's efforts to optimize its capital structure and support its ongoing business initiatives. Everest Medicines' Board, led by Chairman and Executive Director Wei Fu, expressed satisfaction with the successful completion of the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advic","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250801:nNDL2d0FDc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01952","BK1583","BK1574"],"gpt_icon":0},{"id":"2556182938","title":"Everest Medicines Ltd. Files Next Day Disclosure Return with HKEX Announcing Increase of 143,305 New Shares at HKD 19.64 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2556182938","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556182938?lang=en_us&edition=fundamental","pubTime":"2025-08-01 19:39","pubTimestamp":1754048352,"startTime":"0","endTime":"0","summary":"Everest Medicines Ltd. Files Next Day Disclosure Return with HKEX Announcing Increase of 143,305 New Shares at HKD 19.64 Per Share. Everest Medicines Ltd. has filed a Next Day Disclosure Return with the Hong Kong Stock Exchange, announcing the issuance of new shares. The company disclosed the allotment and issue of 143,305 new ordinary shares as part of its Post-IPO Share Option Scheme. The shares were issued at weighted average prices of HKD 22.54 and HKD 19.64491 per share on July 11 and July 14, 2025, respectively.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everest Medicines Ltd. published the original content used to generate this news brief on August 01, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250801:nNDL1ZVL26:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1161","01952","BK1574"],"gpt_icon":0},{"id":"2556051891","title":"Ascentage Pharma to Participate in Evercore China Biotech Summit in Shanghai","url":"https://stock-news.laohu8.com/highlight/detail?id=2556051891","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556051891?lang=en_us&edition=fundamental","pubTime":"2025-08-01 18:09","pubTimestamp":1754042955,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group International, a global biopharmaceutical company focused on unmet medical needs in cancer treatment, will participate in the Evercore China Biotech Summit from August 19 to 21, 2025, in Shanghai, China. The company's management will engage in a fireside chat moderated by the Evercore ISI Research team and hold one-on-one investor meetings during the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 01, 2025, and is solely responsible for the information contained therein","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250801:nNDLc5pQxK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4127","BK1574","06855","EVR"],"gpt_icon":0},{"id":"1144561776","title":"NH HEALTH (06606): Joint Provisional Liquidators Application Filed, Trading Suspension Continues","url":"https://stock-news.laohu8.com/highlight/detail?id=1144561776","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144561776?lang=en_us&edition=fundamental","pubTime":"2025-08-01 16:54","pubTimestamp":1754038467,"startTime":"0","endTime":"0","summary":"NH HEALTH (06606) announced that the company formally filed an application and petition for joint provisional liquidators with the Grand Court on July 8, 2025 (Cayman time). The hearing for the joint...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1219","06606"],"gpt_icon":0},{"id":"2556779893","title":"New Horizon Health Ltd. Applies for Joint Provisional Liquidators to Protect Shareholder Interests Amid Trading Suspension","url":"https://stock-news.laohu8.com/highlight/detail?id=2556779893","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556779893?lang=en_us&edition=fundamental","pubTime":"2025-08-01 16:51","pubTimestamp":1754038285,"startTime":"0","endTime":"0","summary":"New Horizon Health Ltd. has filed an application for the appointment of joint provisional liquidators  with the Grand Court, scheduled for a hearing on August 6, 2025. This step aims to transfer the company's business and affairs to independent professional court officers to safeguard shareholder interests. The JPLs, if appointed, will investigate issues highlighted in previous announcements and explore potential restructuring options. Trading of the company's shares remains suspended since March 28, 2024, pending further updates. Shareholders and investors are advised to exercise caution when dealing with the company's securities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. New Horizon Health Ltd. published the original content use","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250801:nNDL2Chf6B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06606","BK1574","BK1219"],"gpt_icon":0},{"id":"1150553590","title":"AH Statistics | August 1st","url":"https://stock-news.laohu8.com/highlight/detail?id=1150553590","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150553590?lang=en_us&edition=fundamental","pubTime":"2025-08-01 16:16","pubTimestamp":1754036212,"startTime":"0","endTime":"0","summary":"As of the close on August 1st, NE ELECTRIC (00042), HOLLY FUTURES (03678), and ANDRE JUICE (02218) ranked as the top three in AH premium rates, with premium rates of 800.00%, 237.59%, and 222.93%...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0143863784.USD","LU2125910500.SGD","BYDDY","LU1282648689.USD","BK1507","LU0593848301.USD","LU0326950275.SGD","LU2097828474.EUR","LU2097828557.USD","BK1551","LU1868838027.USD","BK1594","LU1880383440.USD","LU2294711713.HKD","00588","LU0823426480.USD","LU0886674414.USD","LU0043850808.USD","BK1202","LU1831875114.USD","LU0737861699.HKD","LU0231483743.USD","LU1226287529.USD","LU1242518857.USD","LU0531971595.HKD","LU0634319403.HKD","LU1808992512.USD","SG9999015945.SGD","LU2476274308.USD","BK1607","LU0561508036.HKD","LU0259732245.USD","LU1807302812.USD","03750","01276","LU0214875030.USD","IE0031814852.USD","BK1214","LU0359201885.HKD","LU1961090484.USD","LU0289961442.SGD","LU0327786744.USD","LU0828237940.HKD","01456","LU1048596156.SGD","LU0061477393.USD","LU0828238088.HKD","LU1282649067.USD","BK1171","SG9999012710.SGD","SG9999012736.USD","LU0890818403.SGD","LU0348788117.USD","BK1144","LU0572944931.SGD","IE00B3M56506.USD","BK1125","LU0181495838.USD","LU2778985437.USD","01211","LU0052750758.USD","LU0589944569.HKD","LU2506951792.HKD","LU0594300179.USD","LU0650527681.SGD","BK1554","LU0348825331.USD","LU0588545904.SGD","01349","BK1592","BK1539","LU0449515922.USD","LU0540923850.HKD","LU0588546209.SGD","01812","LU1770034418.SGD","IE00BF5LJ272.USD","IE0008369823.USD","LU0640798160.USD","LU0359202008.SGD","IE00B0169L03.USD","LU0880133367.SGD","LU0823039010.USD","LU0359201612.USD","01288","SG9999006514.SGD","02338","LU1993786604.SGD","IE00BVYPNQ40.USD","LU1813983027.USD","IE00BZ08YS42.EUR","BK1225","HK0000306701.USD","LU0509642566.USD","LU0244354667.USD","LU0868486357.SGD","LU0163747925.USD","LU0348816934.USD","LU0456827905.SGD","LU0072913022.USD","LU0516422952.EUR","SG9999015986.USD","LU1861214812.USD","BK1141","LU0501845795.SGD","BK1183","IE0034224299.USD","00187","LU0594300419.USD","BK1583","BK1530","LU0048580855.USD","BK1568","LU1880383366.USD","LU0054450605.USD","06127","BK1584","LU1960683339.HKD","IE0032431581.USD","BK1540","LU0862451753.SGD","LU0314109678.HKD","LU1328277881.USD","BK1205","IE00B543WZ88.USD","LU0140636845.USD","LU1046422090.SGD","03143","BK1526","LU2045819591.USD","159982","BK1505","LU0384037296.USD","BK1198","LU1868837722.USD","LU1251922891.USD","LU0449509016.USD","LU1105468828.SGD","00763","LU0315178854.USD","LU0502904849.HKD","BK1574","LU0320764599.SGD","LU1115378108.SGD","HK0000306685.HKD","SG9999004220.SGD","03606","IE00BVYPNP33.GBP","LU0175139822.USD","06680","LU0516423174.USD","IE00BYV24P56.USD","LU0918141705.HKD","LU0348827113.USD","BK1564","SG9999014674.SGD","IE00BMCWC346.EUR","LU1152091754.HKD","LU2449936058.SGD","IE00BD6J9T35.USD","LU0979878070.USD","02359","LU2399975544.HKD","LU1688375341.USD","LU0287142896.SGD","LU1303224171.USD","LU1282649810.SGD","SG9999002828.SGD","02727","02899","LU0828237510.HKD","HK0000320223.HKD","LU0543330566.HKD","LU1008478684.HKD","BK1610","LU0516423091.SGD","IE00BZ08YT58.USD","BK1237","LU0051755006.USD","BK1515","LU2226246903.HKD","LU0823426308.USD","LU0345780281.USD","399300","LU2039709279.SGD","BK1161","LU0315179316.USD","LU0505663152.USD","LU0173614495.USD","LU0463099449.HKD","LU0648948544.HKD","IE0008368742.USD","02238","SG9999015952.SGD","LU0511384066.AUD","LU0229945570.USD","02628","LU0456846285.SGD","LU2242644610.SGD","LU0856984785.SGD","BK1119","LU0211977185.USD","HK0000320264.USD","LU0164865239.USD","LU0370786039.SGD","00042","LU0348814723.USD","LU0289960550.SGD","LU0823038988.USD","BK1223","LU0918141887.USD","LU2348774022.SGD","00991","LU1188198961.HKD","LU0823414551.USD","LU0269904917.USD","SG9999001226.SGD","LU0165289439.USD","BK1550","BK1546","BK1116","IE00BGHQDM52.EUR","LU2249611893.SGD","IE00B031HY20.USD","LU1675838814.USD","01375","BK1560","LU0469268626.HKD","BK1514","IE00B5MMRT66.SGD","LU0417516738.SGD","LU0143863198.USD","02218","BK1544","LU1242518931.SGD","LU0819123356.HKD","02039","LU0348735423.USD","LU0797268264.HKD","LU0345780521.USD","BK1149","BK1506","LU0865486749.SGD","IE00B29SXG58.USD","IE00BZ08YR35.GBP","LU0307460666.USD","LU0605514214.HKD","01033","LU1868837565.USD","LU1282649141.HKD","LU0516422440.USD","06178","LU0417516902.SGD","LU0871576103.HKD","BK1191","BK1576","LU0516422366.SGD","BK1522","LU0039217434.USD","LU0067412154.USD","LU2097828631.EUR","LU2360107325.USD","06185","LU1211504680.USD","BK1231","LU0228367735.SGD","LU0821914370.USD","BK1147","LU0164872284.USD","BK1240","LU2097828714.EUR","03678","01057","LU1794554557.SGD","02611","HYDD.SI","LU2357125470.USD","BK1562","LU0708995583.HKD","LU0588545730.USD","BK1582","LU0289739343.SGD","LU0254981946.USD","IE00B031J352.USD","LU0531970944.HKD","03968","BK1509","LU2097828805.USD","LU0819121731.USD","BK1184","LU0431992006.USD","SG9999015978.USD","LU1504937902.USD","SG9999002463.SGD","LU1023057109.AUD","LU0455707207.USD","81211","SG9999012744.USD","LU1224709979.USD","LU1720050803.USD","BK1529","00300","LU0823414478.USD","BK1521","SG9999006597.SGD","00323","SG9999012728.SGD","LU0488056044.USD","LU0588545490.SGD","LU1152091168.USD","LU0228659784.USD","LU0096374516.USD","LU1719994722.HKD","LU0348805143.USD","LU0106959298.USD","002594","LU2476274720.SGD","LU1861219969.SGD","LU2153592121.USD","LU0084288322.USD","LU1655091616.SGD"],"gpt_icon":1},{"id":"1106536074","title":"UBS Reiterates \"Buy\" Rating on AKESO (09926), Raises Target Price to HK$197.5","url":"https://stock-news.laohu8.com/highlight/detail?id=1106536074","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106536074?lang=en_us&edition=fundamental","pubTime":"2025-08-01 16:04","pubTimestamp":1754035461,"startTime":"0","endTime":"0","summary":"UBS released a research report stating that AKESO's (09926) core product AK112 (ivonescimab) demonstrates significant potential in indications beyond non-small cell lung cancer (NSCLC). In addition...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","BK1574","LU1720050803.USD","LU1794554557.SGD","BK1161","IE00B5MMRT66.SGD","LU0348784397.USD","IE00B543WZ88.USD","IE00BPRC5H50.USD","LU0417516571.SGD","LU0348783233.USD","LU2488822045.USD"],"gpt_icon":0},{"id":"1148385745","title":"A-Share Market Review: Trading Volume Shrinks by Over 300 Billion Yuan, Three Major Indices Close Slightly Lower While Pharmaceutical Stocks Maintain Strength","url":"https://stock-news.laohu8.com/highlight/detail?id=1148385745","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148385745?lang=en_us&edition=fundamental","pubTime":"2025-08-01 15:30","pubTimestamp":1754033444,"startTime":"0","endTime":"0","summary":"On August 1st, A-shares adjusted on reduced trading volume with micro-cap stocks rising again. Over 3,300 stocks closed in the green, with total daily trading volume reaching 1.6 trillion yuan,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","159982","399300","BK1161","09939","159938","BK1574"],"gpt_icon":0},{"id":"1147355320","title":"112% Returns at Peak Before Sudden Departure? Yongying Fund's Chu Kefan Resignation Sparks Speculation as \"Steady Innovation\" Strategy Shows Success Only in Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=1147355320","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147355320?lang=en_us&edition=fundamental","pubTime":"2025-08-01 15:21","pubTimestamp":1754032872,"startTime":"0","endTime":"0","summary":"The summer season's public fund personnel changes often reflect the subtle shifts in industry dynamics. In 2025, healthcare-themed funds have emerged as market leaders with accumulated momentum, with...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","09939","BK1161","159938","BK1574"],"gpt_icon":0},{"id":"2556666458","title":"CARsgen Therapeutics Holdings Ltd. Announces Upcoming Board Meeting to Review Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2556666458","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556666458?lang=en_us&edition=fundamental","pubTime":"2025-08-01 12:05","pubTimestamp":1754021116,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics Holdings Ltd. has announced that a board meeting will be held on Thursday, August 14, 2025. The purpose of the meeting is to consider and approve the interim results of the Group for the six months ended June 30, 2025, and to transact any other business.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief on August 01, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250801:nNDL6DtRdt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1585","BK1574","02171","BK1587"],"gpt_icon":0},{"id":"2556851688","title":"Kintor Pharmaceutical Ltd. Announces Top-Up Placing and New Share Subscription Under General Mandate","url":"https://stock-news.laohu8.com/highlight/detail?id=2556851688","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556851688?lang=en_us&edition=fundamental","pubTime":"2025-08-01 06:13","pubTimestamp":1754000009,"startTime":"0","endTime":"0","summary":"Kintor Pharmaceutical Limited has announced a top-up placing of existing shares and a subscription of new shares under a general mandate. The company, along with Dr. Tong and the Vendor, has entered into an agreement with a Placing Agent. Under this agreement, the Vendor will sell, and the Placing Agent will procure purchasers to buy, on a best effort basis, 20,673,000 shares at a price of HK$2.08 per share. This represents approximately 4.62% of the company's issued share capital. Dr. Youzhi Tong, Chairman of the Board, Executive Director, and CEO of Kintor Pharmaceutical, is overseeing the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kintor Pharmaceutical Ltd. published the original content used to generate this news b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nNDL4x4nvw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","BK1515","09939"],"gpt_icon":0},{"id":"2556485151","title":"BRIEF-Kintor Pharmaceutical To Issue 20.7 MLN Shares For HK$2.08 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2556485151","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556485151?lang=en_us&edition=fundamental","pubTime":"2025-08-01 06:11","pubTimestamp":1753999890,"startTime":"0","endTime":"0","summary":"BRIEF-Kintor Pharmaceutical To Issue 20.7 MLN Shares For HK$2.08 Per ShareAug 1 (Reuters) - Kintor Pharmaceutical Ltd 9939.HK:TO ISSUE 20.7 MILLION SHARES FOR HK$2.08 PER SHAREFurther company coverage: 9939.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nFWN3TS3G9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","BK1574","BK1161","BK1515"],"gpt_icon":0},{"id":"2556851531","title":"Kintor Pharmaceutical -  to Issue 20.7 Mln Shares for HK$2.08 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2556851531","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556851531?lang=en_us&edition=fundamental","pubTime":"2025-08-01 06:10","pubTimestamp":1753999844,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nFWN3TS3G9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1515","BK1574","09939"],"gpt_icon":0},{"id":"2555000050","title":"Kintor Pharmaceutical Completes Patient Enrollment for Phase III Trial of KX-826 Tincture for Male AGA Treatment in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2555000050","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555000050?lang=en_us&edition=fundamental","pubTime":"2025-07-31 17:08","pubTimestamp":1753952938,"startTime":"0","endTime":"0","summary":"Kintor Pharmaceutical Ltd. has announced the completion of patient enrollment in the Phase III stage of a pivotal clinical trial for KX-826 tincture 1.0%, aimed at treating male adult androgenetic alopecia  in China. The trial enrolled 666 patients and is characterized by a multi-center, randomized, double-blind, vehicle-controlled design. This Phase III stage involves a 24-week treatment period, followed by a 2-week safety observation period, across 25 clinical research centers in China. The Phase II stage of the trial previously met its primary endpoints, showing statistically significant and clinically meaningful outcomes in terms of efficacy and safety. The completion of the Phase III stage is anticipated by early 2026. Results from this stage have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informationa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nNDL1ywmpw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","BK1515","09939"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":102,"code":"91000000","status":"200"}]}}